Dr. Olatoyosi Odenike is Professor of Medicine, and Director of the Leukemia Program at the University of Chicago Medicine. Dr. Odenike's research is focused on clinical/translational investigation in myeloid malignancies, including acute and chronic leukemias, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs). She has a particular interest in new drug development in these diseases, with a view to improving patient outcomes. She has served as the Principal Investigator of several clinical/translational trials including NCI sponsored, investigator initiated clinical trials focused on epigenetic modulators, as single agents or in rationally designed combinations. She serves on the Alliance Leukemia Core Committee and is the Chair of the MDS working basket of the NCI Myeloid Malignancies Precision Medicine Initiative, and is co-Chair of the Aplastic Anemia/MDS International Foundation Medical Advisory board. She is an Associate Editor of Blood Advances and served as Section Editor for Advances in Oncology. She has authored/co-authored numerous peer reviewed articles, has served in various editorial, scientific, education and review committees for the National Institutes of Health, American Society of Hematology, American Society of Clinical Oncology and American Board of Internal Medicine.